Topiramate Tablet
Product Images NDC 70518-1196

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-1196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Topiramate 100mg tablet, available in a quantity of 30, manufactured by Cipla USA, Inc. and repackaged by RemedyRepack Ine. It is a prescription medication and should be kept out of the reach of children. The package insert should be consulted for directions of use, and the medication should be stored at a temperature range between 15°C to 30°C (59-86°F). The expiration date and lot number are required, and the NDC# is 70518-1196-00.*
FDA Label Image

Topiramate 100mg 70518 1196 01

Topiramate 100mg 70518 1196 01
Topiramate is a medication in tablet form with a strength of 100 mg. It comes in a quantity of 30 tablets in an Orepack with the Lot number and NDC# indicated. The medication is manufactured by Cipla USA, Inc. from Miami, Florida. This medicine requires a prescription and should be kept out of reach of children. The packaging includes a direction for use and instructions to keep it stored between 20-25°C (68-77°F), with short excursions allowed between 15-30°C (59-86°F) [See USP]. The medication was repackaged by RemedyRepack Ine. from Indiana, PA.*
FDA Label Image

Topiramate 100mg 70518 1196 02

Topiramate 100mg 70518 1196 02
This is a prescription drug called Topiramate, in a 100 mg tablet form manufactured by Cipla USA, Inc. It has an NDC number of 70518-1196-02 and an expiration date and lot number indicated. The drug should be kept out of reach of children and stored at 20-25°C (B-77°F) with excursions permitted at 15-30°C (59-26°F) as per USP guidelines. The package insert should be consulted for directions on use. The drug was repackaged by RemedyRepack Inc, Indiana.*
FDA Label Image

Topiramate 100mg 70518 1196 03

Topiramate 100mg 70518 1196 03
This is a description of a medication produced by Cipla USA, Inc. It contains 100mg of Topiramate and comes in a bottle containing 100 tablets. The package insert should be consulted for directions for use, and it should be stored at a temperature of 20-25°C (B-77°F). However, excursions from this temperature range are permitted to 15-30°C (59-26°F). It was later repackaged by RemedyRepack Inc. of Indiana, PA 15701. The Lot number and expiration date are not available. It is for RX only and should be kept out of reach of children.*
FDA Label Image

Topiramate 100mg 70518 1196 04

Topiramate 100mg 70518 1196 04
Topiramate is a tablet in 100 mg strength, manufactured by Cipla USA, Inc. The medication comes in a package with NDC number 70518-1196-04 and has an expiration date and lot number. It is exclusively prescribed by a registered health practitioner because of its RX ONLY label. The medicine should be kept out of the reach of children and stored at 20-25°C (88-77°F), with excursions permitted at 15-30°C (59-86°F) [See USP]. The Repackaging company is RemedyRepack Ine., Indiana, PA 15701, and the package insert should be consulted before using the drug.*
FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02
This appears to be a chart displaying Cumulative Rates for Time to First Seizure for two groups of individuals (N=234 and N=236) who were given Topiramate at different doses (50 myday and 400 moday). The chart shows time in days on the X-axis and the cumulative rates on the Y-axis.*
FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03
This is a description of the change observed in the double-blind phase of a study related to migraines and the use of Topamax. There are two different doses of Topamax mentioned (100 and 200 mg/day). The study reports an increase of 56 in the average number of monthly migraine periods rate in comparison to a Baseline measurement. The significance of the results is indicated by two asterisks (**p 0001) and (*p <0010) indicating high statistical significance.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.